SomaLogic, a Bolder, CO-based protein biomarker discovery and clinical diagnostics company, raised $10m in funding.
A filing with the S.E.C. lists a single (undisclosed) investor.
Larry Gold, Ph.D., Chairman and CEO, SomaLogic develops novel proteomics systems and applications based on its proprietary aptamer technology. Aptamers are single-stranded DNA and RNA molecules that, like antibodies, can bind to target molecules with high affinity and specificity.
The company recently signed a strategic agreement with Agilent Technologies Inc. (NYSE: A) to expand access to its protein biomarker discovery platform.